WILMINGTON, Mass.--(BUSINESS WIRE)--Jul. 24, 2015--
Charles River Laboratories International, Inc. (NYSE: CRL) announced
today that it has completed the previously announced acquisition of
Celsis International Ltd. for $212 million in cash, subject to certain
post-closing working capital adjustments. The acquisition complements
Charles River Endotoxin and Microbial Detection’s (EMD) position as a
leading provider of rapid endotoxin testing and bacterial identification
for biopharmaceutical manufacturing, and creates the most comprehensive
solution for rapid quality control testing of biopharmaceutical and
consumer products.
Celsis is a leading provider of rapid bacterial detection systems for
quality control testing in the biopharmaceutical and consumer products
industries. Celsis’s systems are principally used for product-release
testing to help ensure the safe manufacture of drugs and consumer
products. The addition of Celsis, with its Advance II™, Accel™, and
Innovate™ systems for non-sterile applications, complements EMD’s
recently introduced PTS-Micro™, a rapid bacterial (bioburden) detection
system for sterile biopharmaceutical applications. The comprehensive EMD
and Celsis portfolio is expected to drive increased adoption of EMD’s
quality control testing solutions across both sterile and non-sterile
applications, as clients seek a single provider for their rapid
product-release testing needs.
Caution Concerning Forward-Looking Statements
This news release includes forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements may be identified by the use of words such as “anticipate,”
“believe,” “expect,” “will,” “may,” “estimate,” “plan,” “outlook,” and
“project” and other similar expressions that predict or indicate future
events or trends or that are not statements of historical matters.
Forward-looking statements include statements in this press release
regarding the acquisition of Celsis International Ltd. (Celsis) and
Charles River’s expectations with respect to the impact of Celsis on the
Company and its product and service offerings; Charles River’s projected
future performance; as well as Charles River’s future growth in the area
of endotoxin and microbial detection products and services.
Forward-looking statements are based on Charles River’s current
expectations and beliefs, and involve a number of risks and
uncertainties that are difficult to predict and that could cause actual
results to differ materially from those stated or implied by the
forward-looking statements. A further description of these risks,
uncertainties, and other matters can be found in the Risk Factors
detailed in Charles River's Annual Report on Form 10-K as filed on
February 17, 2015, as well as other filings we make with the Securities
and Exchange Commission. Because forward-looking statements involve
risks and uncertainties, actual results and events may differ materially
from results and events currently expected by Charles River, and Charles
River assumes no obligation and expressly disclaims any duty to update
information contained in this news release except as required by law.
About Charles River
Charles River provides essential products and services to help
pharmaceutical and biotechnology companies, government agencies and
leading academic institutions around the globe accelerate their research
and drug development efforts. Our dedicated employees are focused on
providing clients with exactly what they need to improve and expedite
the discovery, early-stage development and safe manufacture of new
therapies for the patients who need them. To learn more about our unique
portfolio and breadth of services, visit www.criver.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150724005642/en/
Source: Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc.
Investor Contact:
Susan
E. Hardy, 781-222-6190
Corporate Vice President, Investor Relations
susan.hardy@crl.com
or
Media
Contact:
Amy Cianciaruso, 781-222-6168
Executive Director,
Public Relations
amy.cianciaruso@crl.com